Completed PHASE1 INTERVENTIONAL 2-arm NCT04376554

Effect of Tebipenem on Normal Human Intestinal Microbiota

Phase 1 Study to Evaluate the Effect of Oral Administration of Tebipenem Pivoxil Hydrobromide on Normal Human Intestinal Microbiota in Healthy Volunteers

Sponsor: Iqvia Pty Ltd

Conditions Healthy Volunteers

Interventions TBPM-PI-HBr amoxicillin-clavulanate

Updated 8 times since 2020 Last updated: May 3, 2021 Started: Feb 10, 2020 Primary completion: Apr 6, 2021 Completion: Apr 6, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Healthy Volunteers, this trial is completed. The trial is conducted by Iqvia Pty Ltd and has accumulated 8 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jun 2021 — Jul 2024 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Apr 2021 — Jun 2021 [monthly]

Active Not Recruiting PHASE1
Jan 2021 — Apr 2021 [monthly]

Active Not Recruiting PHASE1

▶ Show 3 earlier versions

Dec 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Oct 2020 — Dec 2020 [monthly]

Recruiting PHASE1

Status: Active Not Recruiting → Recruiting
Jun 2020 — Oct 2020 [monthly]

Active Not Recruiting PHASE1

First recorded

Feb 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Iqvia Pty Ltd
Spero Therapeutics

Data source: Spero Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Huddinge, Sweden